What to Expect on LL-37: Week by Week Timeline

Some individuals report a mild immune-activation response in the first few days, such as low-grade fatigue or body aches. These responses are commonly interpreted as signs that the innate immune system is being upregulated. The antimicrobial activity of LL-37 is thought to begin immediately at the cellular level.

During the first week of a course, the peptide is actively supporting the body's innate defense mechanisms. Patients with biofilm-related concerns sometimes report a temporary flare of symptoms, which providers commonly refer to as a Herxheimer-like reaction. Energy levels may fluctuate during this active phase as the immune system allocates resources.

Many individuals report a shift from the initial immune activation to noticeable improvement in their primary concern during weeks two and three. Skin-related issues, chronic sinus concerns, and other infection-related symptoms are commonly reported to begin resolving. The anti-biofilm properties of LL-37 are thought to be particularly active during this phase.

Standard LL-37 courses are commonly four to six weeks in duration, and the end of the course is a natural assessment point. Many patients describe significant improvement in the concerns that prompted the course. Providers often evaluate whether the response warrants a second course or whether the initial treatment was sufficient.

The immune-modulating effects of LL-37 are commonly reported to persist for weeks to months after the course ends. Many people describe sustained resilience against the recurrence of the concerns that were addressed. Follow-up lab work or imaging, where applicable, can help confirm whether the improvement is durable.